1. Home
  2. MDXG

MDXG

MiMedx Group Inc

Logo MiMedx Group Inc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Founded: N/A Country:
United States
United States
Employees: N/A City: MARIETTA
Market Cap: 924.4M IPO Year: N/A
Target Price: $12.25 AVG Volume (30 days): 791.3K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.37 EPS Growth: N/A
52 Week Low/High: $3.26 - $9.27 Next Earning Date: 04-30-2024
Revenue: $321,477,000 Revenue Growth: 20.03%
Revenue Growth (this year): 13.31% Revenue Growth (next year): 12.95%

Share on Social Networks:

Stock Insider Trading Activity of MiMedx Group Inc (MDXG)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
DOUG RICE MDXG Chief Financial Officer Nov 21 '23 Buy $7.16 5,000 $35,786.50 102,200 SEC Form 4